Christopher S Nabel

List of Publications by Year
in descending order

18 papers	2,017 citations	706676 14 h-index	1051228 16 g-index
18 all docs	18 docs citations	18 times ranked	2683 citing authors

#	Article	IF	Citations
1	Abstract 2150: LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade. Cancer Research, 2022, 82, 2150-2150.	0.4	0
2	Patient-Derived Xenografts to Study Cancer Metabolism: When Does X Mark the Spot?. Cancer Research, 2021, 81, 4399-4401.	0.4	0
3	Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS ONE, 2019, 14, e0218660.	1.1	22
4	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. Oncologist, 2019, 24, 1013-1021.	1.9	15
5	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockadeâ€“refractory idiopathic multicentric Castleman disease. Journal of Clinical Investigation, 2019, 129, 4451-4463.	3.9	87
6	Canakinumab and Lung Cancer: Intriguing, but Is It Real?. Oncologist, 2018, 23, 637-638.	1.9	15
7	Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase. Nature Biotechnology, 2018, 36, 1083-1090.	9.4	154
8	International, evidence-based consensus diagnostic criteria for HHV-8â€“negative/idiopathic multicentric Castleman disease. Blood, 2017, 129, 1646-1657.	0.6	381
9	APOBEC3A efficiently deaminates methylated, but not TET-oxidized, cytosine bases in DNA. Nucleic Acids Research, 2017, 45, 7655-7665.	6.5	65
10	Clinicopathologic analysis of <scp>TAFRO</scp> syndrome demonstrates a distinct subtype of <scp>HHV</scp>â€8â€negative multicentric Castleman disease. American Journal of Hematology, 2016, 91, 220-226.	2.0	208
11	Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematology,the, 2016, 3, e163-e175.	2.2	213
12	Tet2 Catalyzes Stepwise 5-Methylcytosine Oxidation by an Iterative and de novo Mechanism. Journal of the American Chemical Society, 2016, 138, 730-733.	6.6	60
13	Molecular targeting of mutagenic AID and APOBEC deaminases. Cell Cycle, 2014, 13, 171-172.	1.3	3
14	HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood, 2014, 123, 2924-2933.	0.6	259
15	Nucleic acid determinants for selective deamination of DNA over RNA by activation-induced deaminase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14225-14230.	3.3	30
16	AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nature Chemical Biology, 2012, 8, 751-758.	3.9	274
17	The Curious Chemical Biology of Cytosine: Deamination, Methylation,and Oxidation as Modulators of Genomic Potential. ACS Chemical Biology, 2012, 7, 20-30.	1.6	159
18	Demystifying DNA Demethylation. Science, 2011, 333, 1229-1230.	6.0	72